Dr. Ashraf S Ibrahim's Lab @IbrahimLab3

The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center Ashraf S Ibrahim: email: [email protected] lundquist.org/ashraf-s-ibrah… Torrance,CA Joined January 2019

Tweets

199
Followers

382
Following

164
Likes

173

Dr. Ashraf S Ibrahim's Lab @IbrahimLab3

2 weeks ago

Honored to welcome @SenBillCassidy to @the_lundquist. I showed him @IbrahimLab3, where we study host–pathogen interactions, develop immunotherapies for mucormycosis, and advance vaccines against drug-resistant infections. Grateful for his support of biomedical research.

0 4 14 663 2

Download Image

The Lundquist Institute @the_lundquist

2 months ago

IT'S A TWO-FER! A huge congratulations to TLI Investigator @IbrahimLab3 for receiving the 43rd Kuwait Prize by the @KuwaitFAS. This prestigious award honors Kuwaiti and Arab scientists for their exceptional scientific and intellectual contributions on a global scale.🚀 Dr.…

0 2 3 174 1

Download Image

The Lundquist Institute @the_lundquist

6 months ago

Mucormycosis is a fungal infection that causes severe disease and fatality, especially in immunocompromised individuals. While vaccines and immunotherapeutics have been available in combating viral and bacterial infections, approved antifungal immunotherapies are lacking. Thanks…

Science Translational Medicine @ScienceTM

6 months ago

0 0 4 1K 0

Download Image

0 2 2 231 0

The Lundquist Institute @the_lundquist

6 months ago

Mucormycosis is a fungal infection that causes severe disease and fatality. “Mucormycosis usually occurs in patients who suffer from weakened immune system, such as patients with poorly controlled diabetes, cancer patients undergoing chemotherapy, and transplant patients,” says…

0 5 9 339 1

Download Image

Dr. Ashraf S Ibrahim's Lab @IbrahimLab3

6 months ago

Happy to see our paper describing the activity and MoA of a humanized MAb (VX-01) against mucormycosis published in Sciences Translational Medicine. This takes us a step closer to clinical testing on the road to provide better care for this lethal fungal infection.

0 2 5 350 0

Dr. Ashraf S Ibrahim's Lab @IbrahimLab3

6 months ago

A humanized antibody against mucormycosis targets angioinvasion and augments the host immune response | Science Translational Medicine science.org/doi/10.1126/sc…

0 0 7 106 1

The Lundquist Institute @the_lundquist

a year ago

🔬✨ National Immunization Awareness Month✨🔬 This August, we spotlight the critical role of vaccines and immunotherapies in our fight against infectious diseases. Learn more about @IbrahimLab3's work and @the_lundquist below: instagram.com/p/C-6AZhTyhd8/…

0 1 1 186 1

Dora Corzo, MD, PhD 🇲🇽🏴󠁧󠁢󠁳󠁣󠁴󠁿 @forestcita

a year ago

That’s a wrap! After 3 weeks in L.A I just have thankful words for the fantastic and welcoming @IbrahimLab3. Loads of learning at @the_lundquist see you later California @BallouLab @MRCcmm #Collaboration #STEM #FungiFriday

1 3 15 692 1

Download Image

The Lundquist Institute @the_lundquist

a year ago

@the_lundquist Investigator Ashraf Ibrahim, PhD, has been selected by the Medical Mycology Society of the Americas (MMSA) to receive the 2024 Billy H. Cooper Award for his continuous outstanding achievement in clinical mycology. TLI congratulates Dr Ibrahim for this high honor.

2 4 19 519 1

Download Image

MSGERC @MSG_ERC

2 years ago

Congrats @kierenamarr @davidrandes Nathan Wiederhold @doctorfungus @IbrahimLab3 Bill Steinbach etc on this achievement!

0 5 16 2K 2

Dr. Ashraf S Ibrahim's Lab @IbrahimLab3

2 years ago

Great seminar about #aspergillus by Gustavo Goldman, from @FungalSao at @the_lundquist

0 0 12 532 0

Download Image

Dr. Ashraf S Ibrahim's Lab @IbrahimLab3

2 years ago

Vitalex Biosciences, a spinoff start-up company of The Lundquist Institute for Biomedical Innovation, is proud to announce today that its VX-01 monoclonal antibody program targeting the debilitating indication of mucormycosis has been awarded an SBIR Phase 2 grant from NIAID/NIH.

Vitalex Bioscience @VitalexBioscien

2 years ago

1 0 1 2K 0

0 2 15 2K 0

Martin Hoenigl🇺🇦🇦🇹 @martinhoenigl

3 years ago

Ibrexafungerp, a Novel Triterpenoid Antifungal in Development for the Treatment of Mold Infections @IbrahimLab3 @Ana_Alastruey @Nkechi93564130 mdpi.com/1904744

0 7 18 0 1

Raul Macias Gil @RMGmdID

3 years ago

Dr @IbrahimLab3 from @HarborUCLA_ID presenting potential novel #antifungals vs #mucor @IDWeek2022

0 2 9 0 0

Download Image

Vitalex Bioscience @VitalexBioscien

3 years ago

VX01 targets the fungal invasion,CotH3 and is proven in preclinical testing to treat mucormycosis alone or synergistically with FDA-approved antifungal agents.

1 1 2 0 0

Vitalex Bioscience @VitalexBioscien

3 years ago

The award was issued by NIAID Preclinical service (PCS) to select a Research Cell Bank to further the establishment of a Master Cell Bank. Vitalex also recently received a competitive score of 24 on a Phase II SBIR grant.

1 1 1 0 0

Vitalex Bioscience @VitalexBioscien

3 years ago

If the Phase II SBIR grant is funded, Vitalex will be able to conduct manufacturing, test VX01 in tissue cross-reactivity studies and conduct IND-enabling GLP-toxicity studies.